Astrana Health (NASDAQ:ASTH – Get Free Report) was upgraded by Macquarie to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.
ASTH has been the subject of a number of other reports. TD Cowen started coverage on shares of Astrana Health in a report on Monday, October 14th. They set a “buy” rating and a $66.00 target price for the company. KeyCorp initiated coverage on Astrana Health in a report on Friday, October 11th. They issued a “sector weight” rating on the stock. Robert W. Baird upped their target price on Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, BTIG Research lifted their price target on Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, October 3rd. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $65.17.
Get Our Latest Analysis on Astrana Health
Astrana Health Stock Down 3.5 %
Astrana Health (NASDAQ:ASTH – Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The firm had revenue of $478.71 million for the quarter, compared to analysts’ expectations of $462.01 million. During the same period in the previous year, the business earned $0.47 earnings per share. Equities analysts expect that Astrana Health will post 1.16 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Astrana Health
Large investors have recently made changes to their positions in the business. GAMMA Investing LLC acquired a new position in shares of Astrana Health in the third quarter worth $34,000. Nisa Investment Advisors LLC purchased a new stake in shares of Astrana Health during the 3rd quarter worth about $35,000. KBC Group NV acquired a new stake in shares of Astrana Health during the 3rd quarter valued at about $70,000. Quarry LP acquired a new position in Astrana Health in the third quarter worth approximately $77,000. Finally, Quest Partners LLC bought a new position in Astrana Health during the third quarter valued at approximately $133,000. Institutional investors and hedge funds own 52.77% of the company’s stock.
About Astrana Health
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Recommended Stories
- Five stocks we like better than Astrana Health
- How to Invest in Biotech Stocks
- AppLovin Insiders Sell Shares: Stock Price Indicated Higher
- What Does Downgrade Mean in Investing?
- Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector Rally
- What Are the FAANG Stocks and Are They Good Investments?
- Salesforce’s Clear Path to $400 and Beyond
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.